Literature DB >> 15003452

Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

Robert X Xu1, Warren J Rocque, Millard H Lambert, Dana E Vanderwall, Michael A Luther, Robert T Nolte.   

Abstract

Phosphodiesterase catalyzes the hydrolysis of the intracellular second messenger 3',5'-cyclic AMP (cAMP) into the corresponding 5'-nucleotide. Phosphodiesterase 4 (PDE4), the major cAMP-specific PDE in inflammatory and immune cells, is an attractive target for the treatment of asthma and COPD. We have determined crystal structures of the catalytic domain of PDE4B complexed with AMP (2.0 A), 8-Br-AMP (2.13 A) and the potent inhibitor rolipram (2.0 A). All the ligands bind in the same hydrophobic pocket and can interact directly with the active site metal ions. The identity of these metal ions was examined using X-ray anomalous difference data. The structure of the AMP complex confirms the location of the catalytic site and allowed us to speculate about the detailed mechanism of catalysis. The high-resolution structures provided the experimental insight into the nucleotide selectivity of phosphodiesterase. 8-Br-AMP binds in the syn conformation to the enzyme and demonstrates an alternative nucleotide-binding mode. Rolipram occupies much of the AMP-binding site and forms two hydrogen bonds with Gln443 similar to the nucleotides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003452     DOI: 10.1016/j.jmb.2004.01.040

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  30 in total

1.  Challenges in the determination of the binding modes of non-standard ligands in X-ray crystal complexes.

Authors:  Alpeshkumar K Malde; Alan E Mark
Journal:  J Comput Aided Mol Des       Date:  2010-11-04       Impact factor: 3.686

2.  Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance.

Authors:  Chris Williams
Journal:  Mol Divers       Date:  2006-09-21       Impact factor: 2.943

3.  Selectivity in enrichment of cAMP-dependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins.

Authors:  Thin Thin Aye; Shabaz Mohammed; Henk W P van den Toorn; Toon A B van Veen; Marcel A G van der Heyden; Arjen Scholten; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2008-12-31       Impact factor: 5.911

Review 4.  Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies.

Authors:  Stephen J Hill; Christine Williams; Lauren T May
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Authors:  Shenping Liu; Mahmoud N Mansour; Keith S Dillman; Jose R Perez; Dennis E Danley; Paul A Aeed; Samuel P Simons; Peter K Lemotte; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

6.  Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.

Authors:  Ana Santos de Medeiros; Arlene R Wyman; Manal A Alaamery; Christina Allain; F Douglas Ivey; Lili Wang; Hai Le; James P Morken; Alawi Habara; Cuong Le; Shuaiying Cui; Adam Lerner; Charles S Hoffman
Journal:  Cell Signal       Date:  2017-09-01       Impact factor: 4.315

Review 7.  Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors.

Authors:  George G Holz; Oleg G Chepurny; Frank Schwede
Journal:  Cell Signal       Date:  2007-07-25       Impact factor: 4.315

8.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

9.  Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Authors:  Naga Srinivas Tripuraneni; Mohammed Afzal Azam
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810

10.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Authors:  Qing Huai; Yingjie Sun; Huanchen Wang; Dwight Macdonald; Renée Aspiotis; Howard Robinson; Zheng Huang; Hengming Ke
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.